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Abstract: STAT3 mediates cytokine and growth factor receptor signalling, becoming 
transcriptionally active upon tyrosine 705 phosphorylation (Y-P). Constitutively Y-P 
STAT3 is observed in many tumors that become addicted to its activity, and STAT3 
transcriptional activation is required for tumor transformation downstream of several 
oncogenes. We have recently demonstrated that constitutively active STAT3 drives a 
metabolic switch towards aerobic glycolysis through the transcriptional induction of Hif-1α 
and the down-regulation of mitochondrial activity, in both MEF cells expressing 
constitutively active STAT3 (Stat3C/C) and STAT3-addicted tumor cells. This novel 
metabolic function is likely involved in mediating pre-oncogenic features in the primary 
Stat3C/C MEFs such as resistance to apoptosis and senescence and rapid proliferation. 
Moreover, it strongly contributes to the ability of primary Stat3C/C MEFs to undergo 
malignant transformation upon spontaneous immortalization, a feature that may explain the 
well known causative link between STAT3 constitutive activity and tumor transformation 
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under chronic inflammatory conditions. Taken together with the recently uncovered role of 
STAT3 in regulating energy metabolism from within the mitochondrion when phosphorylated 
on Ser 727, these data place STAT3 at the center of a hub regulating energy metabolism 
under different conditions, in most cases promoting cell survival, proliferation and 
malignant transformation even though with distinct mechanisms. 




The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) is activated 
downstream of many cytokine and growth factor receptors, resulting in tyrosine phosphorylation, 
dimerization via reciprocal phosphotyrosine-src homology (SH)-2 interactions and translocation to the 
nucleus, where it binds to responsive elements on gene promoters. STAT3 can also be phosphorylated 
on serine residue 727 (S-P) within its carboxyl-terminal Transcription Activation Domain [1,2], which 
is thought to provide full trans-activating properties to the Y-P protein for optimal induction of a 
subset of target genes [3]. 
STAT3 target genes and functions vary depending on the cellular system, but in most instances 
correlate with cell survival and proliferation. Under physiological conditions, STAT3 activation is 
transient and tightly regulated by negative feedback mechanisms mediated, among others, by 
suppressor of cytokine signal (SOCS) and protein inhibitor of activated STAT (PIAS) proteins [4,5]. 
On the other hand, persistent STAT3 activation is commonly observed in tumors of different origin 
and during chronic inflammation, downstream of continuous cytokine/growth factor stimulation or of 
constitutive activity of non-receptor tyrosine kinases such as cSrc [6]. A direct role in oncogenesis was 
demonstrated by the ability of the artificially mutated form Stat3C to lead to malignant transformation 
when overexpressed in immortalized fibroblasts and epithelial cells [7]. STAT3 inhibition in many 
tumor models/primary tumor cells leads to loss of survival and proliferation, suggesting addiction of 
tumor cells to STAT3 activity [8,9]. Accordingly, STAT3 is required for malignant transformation by 
many oncogenes, in primis vSrc, in a number of cell types [10]. 
In tumors, STAT3 is known to exert a number of well established functions correlating to 
transcriptional activation of its target genes, including regulation of cell-cycle progression, apoptosis, 
tumor angiogenesis, invasion, metastasis, and tumor cell evasion from the immune system, reflecting 
the involvement of this factor in multiple steps of the oncogenic program [11]. Additionally, STAT3 is 
considered as a key player in mediating inflammation-driven tumorigenesis, being constitutively 
activated by chronically high levels of the pro-inflammatory cytokine IL-6 [12]. 
1.1. STAT3 Differentially Modified Forms and Cell Metabolism 
Aberrant regulation of cell metabolism plays a central role in deterring the survival and growth 
features of malignant cells. For example, most tumor cells display a metabolic switch towards aerobic 
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glycolysis, with increased glycolysis and decreased oxidative phosphorylation, even under conditions 
of high oxygen tension [13–15]. This phenomenon is thought to favor the synthesis of essential cellular 
components required for fast cell duplication. Recently, a number of observations have suggested that 
STAT3 can act as a central regulator of cell metabolism at multiple levels, which may represent a core 
function in promoting growth/survival of biologically distinct tumors [16]. Interestingly, specific and 
often unconventional functions have been assigned to the differentially modified forms of this factor, 
as summarized below. 
First, STAT3 was shown to localize to mitochondria, where its S-P form enhances coupled 
Complex I and II activity and reduces ROS production, while inducing aerobic glycolysis [17,18]. This 
function enhances cell survival under stress conditions such as heart ischemia, and is required for cell 
transformation downstream of Ras oncogenes, which elicit S, but not Y, phosphorylation of STAT3. 
Additionally, STAT3 was shown to interact with cyclophilin F (best known as cyclophilin D) in the 
mitochondrial matrix, thus inhibiting the opening of the mitochondrial permeability transition pore 
(MPTP) and Calcium-induced apoptosis [19]. STAT3 S-P is known to enhance its interaction with the 
complex I component GRIM-19, responsible for its mitochondrial translocation [20]. Although how 
STAT3 phosphorylation can be regulated within the mitochondrion is not understood, the phosphatase 
SHP2 was proposed as a potential player in dephosphorylating mitochondrial STAT3 [21]. 
Y-P STAT3 was also recently shown to play important roles in regulating energy metabolism. 
Indeed, we have demonstrated that constitutively Y-P STAT3 can promote aerobic glycolysis and 
down-regulate mitochondrial activity, partly acting via transcriptional induction of its well-recognized 
transcriptional target Hif-1α [22]. The functional interaction between these two transcription factors is 
further extended by the observation that STAT3 can specifically bind to HIF-1α target genes 
promoters, allowing the formation of transcriptionally active HIF-1α/RNA Polymerase II complexes [23]. 
Both these activities can contribute to the reported ability of constitutively active STAT3 to act as a first 
hit in oncogenic transformation [24]. Finally the pyruvate kinase M2 isoform (PKM2), an essential 
regulator of aerobic glycolysis that can be induced by HIF-1α, was shown to be able to directly promote 
chronic STAT3 Y-P. Thus STAT3, HIF-1α and PKM2 appear to take part in a positive feedback loop 
responsible for supporting cell proliferation and survival [25,26]. 
Protein acetylation, a crucial post-translational modification that affects gene expression by 
modulating both chromatin structure and the activity of many transcription factors, is a key factor in 
regulating proliferation and energy metabolism in both normal and transformed cells [27]. STAT3 can 
be acetylated (Ac-STAT3) by the CBP/p300 histone acetyltransferase in response to cytokines and 
growth factors, favoring dimer stability, tyrosine phosphorylation and transcriptional activity [28]. 
Interestingly, STAT3 acetylation was shown to occur in the nucleus thanks to a complex with the 
cancer stem cell marker CD44 and p300, leading to the binding to the cyclin D1 promoter, thus 
triggering increased expression and cell proliferation [29]. Ac-STAT3 is also thought to favor 
tumorigenesis by forming a complex with DNA methyltransferase 1 (DNMT1), thus leading to DNA 
methylation and silencing of tumor suppressor genes [30]. Along with other histone deacetylases, the 
NAD-dependent silent information regulator protein (SIRT)1 has been implicated in STAT3 
deacetylation, in turn leading to reduced Y phosphorylation and transcriptional activity [31]. Recently, 
SIRT1 was also shown to indirectly modulate STAT3 S-P and its mitochondrial functions, since Sirt1-null 
MEF cells display high S-P STAT3 levels in mitochondria and increased mitochondrial activity [32]. 
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Another SIRT family member, SIRT3, which localizes specifically to mitochondria, is implicated in 
down-regulating mitochondrial respiration. Sirt3 genetic ablation leads to a metabolic switch towards 
aerobic glycolysis due to increased ROS production and consequent HIF-1α stabilization [33]. No 
direct interactions between SIRT3 and STAT3 have however been reported so far. Another player may 
be the mTORC1 inhibitor REDD1, a known HIF-1α target that localizes to mitochondria. REDD1 
inactivation results in increased ROS production, stabilization of HIF-1α and tumorigenesis [34]. 
These observations suggest that SIRT3 and REDD1 might cooperate in mitochondria to sustain 
oxidative phosphorylation and ROS removal. Whether their activities may somehow regulate the 
functions of mitochondrial STAT3 remains to be established. On the other hand, the nutrient-sensing 
mTOR pathway has been implicated in regulating STAT3 activities by enhancing both its Y- and  
S-phosphorylation [35–37]. 
Interestingly, STAT3 was recently shown to play a role in the regulation of the autophagic pathway, 
another important metabolic process that has been implicated both positively and negatively in 
tumorigenesis [38]. This occurs in the cytoplasm, where non-phosphorylated STAT3 can interact via 
its SH2 domain with the autophagy inducer PKR/EIF2AK2 kinase, inhibiting its activity [39]. This 
function can be inhibited, in addition to interfering with the SH2 domain by means of specific 
compounds, by the activation of STAT3 Y-P, which decreases the pool of cytoplasmic STAT3 
available for the interaction with PKR. 
STAT3 appears to function as a hub to integrate different pro-survival and growth signals at the level 
of the energy and respiratory metabolism, via nuclear, mitochondrial and cytoplasmic activities mediated 
by its differentially modified forms [16]. Here, we discuss some of these results and how they may fit 
together in a multidimensional vision of STAT3 functions under conditions of aberrant activation. 
2. Results and Discussion 
2.1. STAT3 Constitutive Activation Elicits Pre-Oncogenic Features in Stat3C/C MEFs. 
Mice homozygous for the Stat3C k/in allele exhibited increased nuclear localization, prolonged Y-P 
and enhanced transcriptional activity in response to cytokine stimuli in several tissues as well as in 
mouse embryonic fibroblasts (MEFs) [40]. Compared to wild-type control cells, Stat3C/C cells displayed 
enhanced proliferation and accelerated cell cycle, with a more rapid transition through the S-phase [22,24]. 
In addition, replicative senescence was strongly delayed and cells were highly resistant to apoptosis 
induced by different stimuli such as UV treatment (23% of apoptotic cells after 24 h, compared to 45% 
in the wild type controls, Figure 1A), H2O2 treatment and serum starvation ([22] and not shown). 
Interestingly, Stat3C/C MEFs became more readily immortalized than their wild type counterparts when 
subjected to the 3T3 spontaneous immortalization protocol (EF), and maintained significant resistance 
to multiple apoptotic stimuli, similar to the primary cells (19% of dead cells upon UV light exposure 
compared to 33% in wild type cells, Figure 1B) [24]. 
These features reflect the known activities of STAT3, promoting cell survival and proliferation, and 
suggest that low levels of constitutively active STAT3 can promote pre-oncogenic features in primary 
MEF cells. 
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Figure 1. Primary (A) and immortalized (B) Stat3C/C MEFs are protected from apoptotic 
stimuli. Stat3WT/WT or Stat3C/C cells were treated with UV-B (10 J/m2) and after 24 h analyzed 
by flow cytometry for quantification of Annexin V positive cells. Aerobic glycolysis of 
Stat3WT/WT and Stat3C/C primary (C) and immortalized (D) MEFs was assessed by Taqman 
RT-PCR for Hif-1α and Pdk-1 mRNA levels and lactate production. Gene expression and 
lactate accumulation were also analyzed in MDA-MB-468 tumor cells (E), either untreated 
or treated with S3I (STAT3 inhibitor). All the above parameters were also measured upon 
Hif-1α silencing (shHif-1α). Bars represent mean values ± SEM, of three independent 
experiments. Modified from references [22,24], according to the journals’ license terms. 
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2.2. Constitutive STAT3 Activity Induces a Metabolic Switch to Aerobic Glycolysis in MEFs and 
Tumor Cell Lines 
A comparison of gene expression profiles in primary Stat3C/C and Stat3WT/WT MEFs performed via 
microarray analysis showed more than one thousand differentially expressed genes [22]. Gene 
Ontology (GO) analysis of up-regulated mRNAs revealed the presence of several genes involved in 
aerobic glycolysis including hypoxia inducible factor (Hif)-1α (Figure 1C), which is a known STAT3 
transcriptional target [41]. The up-regulation of several known HIF-1α target genes, including pyruvate 
dehydrogenase kinase (Pdk)-1, the glucose transporter Glut1 and several enzymes involved in glycolysis 
was also validated (Figure 1C and data not shown). These alterations correlated with enhanced 
production of lactate and increased intake of glucose (Figure 1C and data not shown). Thus, Stat3C/C 
MEFs appear to display a phenotype highly reminiscent of the well-known Warburg effect detected in 
most cancer cells, with glucose metabolism occurring mainly via aerobic glycolysis. These features 
were maintained in the immortalized Stat3C/C cells [24], which displayed STAT3-dependent increased 
levels of Hif-1α mRNA and of several of its target genes as well as higher lactate production (Figure 1D). 
These data demonstrated that low levels of aberrantly continuous STAT3 activation are sufficient to 
drive a metabolic switch towards aerobic glycolysis, which in turn is known to promote the ability of 
cancer cells to rapidly proliferate and to drive their plasticity to adapt and survive in environments of 
limiting oxygen concentrations. This novel function may explain the addiction for STAT3 shown by so 
many biologically different tumors. In order to verify these conclusions in a more physiological 
context with non mutant STAT3, we analyzed the expression of Hif-1α, Pdk-1 and other glycolytic 
genes in STAT3-dependent tumor cell lines, in the presence or absence of the S3I.201 STAT3 
inhibitor. In agreement with the idea of STAT3 promoting aerobic glycolysis, all three cell lines tested, 
i.e., MDA-MB-468, SKBR3 and DU145, displayed high expression of the Hif-1α and Pdk-1 mRNAs 
and high lactate production, which could be significantly down-regulated by STAT3 inhibition  
(Figure 1E and data not shown, [22]). 
The relevance of this novel metabolic STAT3 function in supporting the viability of tumor cells was 
also confirmed in vivo on xenograft tumors of MDA-MB468 cells. Since the levels of glucose uptake 
are considered a direct indication of glycolytic metabolism, we assessed them by means of PET analysis 
with the radioactive glucose-analogue 18F-FDG [22] (Figure 2). The tumors of control mice, not treated 
with the S3I compound, displayed regular growth and progressively increasing ratio between glucose 
uptake and tumor volume. Thus, glycolysis levels tended to increase even faster than tumor volume, 
indicating progressively enhanced Warburg metabolism. In contrast, treatment with the S3I inhibitor 
determined a growth arrest of the tumor, which correlated with a reduction in glucose uptake already 
after 3 days. These observations suggest that the inhibition of STAT3 activity has prominent effects on 
glucose metabolism also in vivo, and that this represents an important part of its pro-oncogenic activities. 
Transcriptional induction is normally not believed sufficient to enhance HIF-1α expression at the 
protein level, due to its continuous proteasome-mediated degradation occurring in the absence of 
specific signals such as hypoxia or growth factors stimulation [42]. However, we could show that 
Stat3C/C MEFs display higher HIF-1α protein expression than their wild type controls [22]. This 
suggests that continuous, low level mRNA induction triggered by constitutively active STAT3 can 
lead to a small (50%) increase in HIF-1α protein levels that is sufficient to enhance protein activity. In 
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turn, enhanced HIF-1α activity could explain the STAT3-dependent metabolic switch towards 
glycolysis described above. Indeed, shRNA-mediated silencing of Hif-1α completely normalized 
glycolysis levels in both primary and immortalized Stat3C/C MEFs, leading to down-regulation of many 
genes involved in aerobic glycolysis including Pdk-1, and to reduction of lactate production, glucose 
intake and sensitivity to glucose deprivation (Figure 1C,D and [22,24]). Hif-1α silencing could also 
down-regulate Pdk-1 expression and lactate production in STAT3-addicted tumor cells, to an extent 
similar to that obtained by STAT3 silencing (Figure 1E). Thus, STAT3-dependent Hif-1α induction 
appears to represent the main mechanism responsible for the increased glycolysis and enhanced 
glucose dependence observed in the Stat3C/C MEFs, strongly contributing to the in vivo growth of 
MDA-MB-468 tumor xenografts. Of note, increased HIF-1α activity may enhance PKM2 expression 
and initiate the positive feedback loop leading to continuous STAT3 Y-P [25]. 
Figure 2. In vivo STAT3-dependent glycolysis of MDA-MB-468 tumor cells, measured by 
PET analysis as 18F-FDG uptake. Mice were inoculated with MDA-MB-468 cells and tumors 
let grow up to 60 mm3 prior to S3I treatment (day 0). 18F-FDG was injected and images 
acquired at days 0, 3 and 8 after the first S3I treatment. (A) Representative images (sagittal 
and coronal sections) of one control and one S3I-treated mouse 8 days after treatment; (B) 
Tumor volumes were measured with a caliper and indicated as percentage of growth relative 
to day 0; (C) The lower graph represents the variation of glucose uptake normalized over 
tumor volume at the indicated times after the first S3I treatment. Quantitative image analysis 
of tracer uptake was evaluated by drawing region of interest (ROI) of tumor on the transaxial 
images. Note decreased glucose uptake at day 3 (d3) and 8 (d8) upon S3I treatment, compared 
to constant tumor volume. % of 18F-FDG uptake = (SUVd=n − SUVd=0) × 100/ SUVd=0.  
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Despite a well-accepted pro-tumorigenic role, STAT3 activity has also been correlated with good 
prognosis in specific tumors [43,44] and mouse models of colorectal [45] and thyroid cancer [46]. In 
particular in the latter, STAT3 Y-P negatively correlates with tumor size and aggressiveness in human 
papillary thyroid carcinomas, and appears to paradoxically negatively regulate Hif-1α expression and 
aerobic glycolysis under hypoxic conditions [46]. These observations suggest that the specific role of 
STA3 can be strongly tissue- and context-dependent. 
2.3. Reduced Mitochondrial Activity in Cells with a Constitutive Activation of STAT3 
In addition to enhanced aerobic glycolysis, tumor cells that have undergone the Warburg effect also 
display decreased oxidative respiration in mitochondria, which is partly the consequence of deviating 
pyruvate towards glycolysis and may contribute to down-regulate ROS production and counteract 
senescence [47]. Interestingly, in parallel to the up-regulation of genes involved in glycolysis, microarray 
analysis of Stat3C/C and Stat3WT/WT MEFs showed significant down-regulation of genes belonging to 
GO categories related to mitochondrial function [22]. In particular, the expression of nuclear-encoded 
genes involved in mitochondrial function was significantly reduced, correlating with reduced protein 
levels of representative components of the Electron Transport Chain (ETC). This down-regulation may 
lead to reduced cellular respiration, similar to what observed in cancer cells displaying aerobic 
glycolysis and the Warburg effect. Mitochondrial activity was assessed as the measure of Ca2+ uptake 
upon ATP stimulation [48], which directly regulates oxidative phosphorylation [49–52]. Indeed, 
mitochondrial Ca2+ uptake was significantly reduced as compared to controls in primary (Figure 3A) as 
well as immortalized (Figure 3B) Stat3C/C MEFs. Accordingly, both mitochondrial ATP production and 
basal respiratory chain activity were reduced [22]. Despite this observation, the ATP:ADP ratio was 
increased in the Stat3C/C MEFs, confirming that these cells rely on energy production generated via 
glycolysis [22]. Similar to MEFs, also the STAT3-addicted MDA-MB-468, SKBR3 and DU145 
human tumor cells exhibited relatively low mitochondrial activity that was dependent on STAT3, since 
it could be enhanced by treatment with the S3I inhibitor (Figure 3C and [22]). Interestingly, a reduced 
mitochondrial Ca2+ uptake dramatically blunts the apoptotic response [53] preventing the mitochondrial 
permeability transition pore opening [54], as observed in Stat3C/C cells [22]. 
Importantly, and in contrast to what observed for glycolysis, the reduced mitochondrial activity 
observed in primary MEFs was independent from HIF activity, as shown by the failure of Hif-1α 
silencing to increase Ca2+ uptake (Figure 3A and [22]). One possible explanation is the observed 
STAT3-dependent down-regulation of nuclear genes encoding for mitochondrial proteins and the 
consequent reduced levels of ETC components. Accordingly, Hif-1α silencing could not rescue the 
expression of these genes [22]. Mitochondrial activity was independent of HIF-1α levels also in the 
MDA-MB-468 cells (not shown). 
In contrast to primary cells, in immortalized MEFs Hif-1α silencing could enhance Ca2+ uptake in 
both wild type and Stat3C/C cells (Figure 3B), suggesting that its activity contributes to the control of 
oxidative phosphorylation in immortalized fibroblasts regardless of their genotype [24]. However, the 
levels of Ca2+ uptake remained significantly lower in Stat3C/C cells as compared to the wild type 
controls even after Hif-1α silencing. Thus, the control of mitochondrial activity in these cells remains 
at least partly HIF-independent also in immortalized cells. 
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Figure 3. Decreased mitochondrial activity of primary (A) or immortalized (B) Stat3C/C 
MEFs, and of MDA-MB-468 tumor cells (C). MEFs of the indicated genotypes, either 
silenced or not for Hif-1α, were transduced with a mitochondrial-targeted aequorin  
(AEQ) [55]. Aequorin activity was measured upon challenging with 100 μM ATP as 
indicated. Mitochondrial Ca2+ response was assessed in MDA-MB-468 cells treated or not 
with S3I for 12 h (C). Data are representative of at least 10 traces, each from three 
independent experiments. Modified from references [22,24], according to the journals’ 
license terms. 
 
Taken together, these data suggest that constitutively active STAT3, observed downstream of 
continuous stimulation by inflammatory cytokines such as IL-6 and oncogenes, promotes a Warburg-like 
metabolic switch via two distinct nuclear mechanisms (Figure 4). First, the induction of Hif-1α expression, 
which in turn mediates the up-regulation of genes involved in glycolysis. This increases glucose 
consumption and promotes fast proliferation, leading to glucose dependence like in glycolytic cancer cells. 
Second, the down-regulation of mitochondrial activity, which is totally or partly HIF-1α-independent and 
may be caused by the reduced levels of ETC components, in turn caused by reduced expression of 
nuclear genes encoding for mitochondrial proteins. Although at present we cannot determine whether 
STAT3 can directly affect their transcription, we did not observe any enrichment in STAT3 responsive 
elements in the promoters of the down-regulated genes [56]. Thus, we favor the idea of an indirect 
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regulation of a common repressor or of targeting microRNA(s). Impaired mitochondrial activity may 
contribute to the reduced production of ROS observed in the Stat3C/C MEFs, which in turn is likely 
correlated to their high resistance to apoptosis and senescence, two hallmarks of cellular 
transformation. On the other hand, STAT3 may help regulating energy metabolism also via different 
mechanisms. For example, it has been reported that human and murine hepatocellular carcinomas 
show significantly reduced expression of gluconeogenic enzymes including PCG1α, mediated by the 
up-regulation of miR-23a expression by an activated IL-6-STAT3 signalling pathway [57]. This leads 
to increased glucose release, thus sustaining fast proliferation. On the other hand, PCG1α is known to 
affect the levels and activity of numerous mitochondrial proteins, positively regulating mitochondrial 
respiration [58,59], and to control ROS levels by regulating the expression of numerous ROS-detoxifying 
enzymes [60]. Thus, STAT3-dependent down-regulation of PCG1α may also contribute to down-regulate 
the levels of ETC components as well as mitochondrial activity. 
Figure 4. Constitutively active STAT3 regulates mRNA expression of metabolic genes.  
Y-P STAT3 is the downstream effector of several oncogenic signals. Constitutively activated 
STAT3 translocates into the nucleus where it induces aerobic glycolysis through (i) the  
up-regulation of HIF-1α, which in turn mediates the induction of several mRNA involved 
in glycolysis; and (ii) the down-regulation of mitochondrial genes and of ETC-complexes, 
leading to reduced mitochondrial activity. The heatmaps display the mean log2 fold change 
of signal intensity between Stat3C/C and wild type MEFs as assessed by microarray analysis. 
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Despite the decreased expression of about 500 mitochondrial genes and the normal mitochondrial 
morphology [22], the mitochondrial mass was increased in the Stat3C/C MEFs [61], suggesting a 
potential role of STAT3 in mitochondrial biogenesis. This might occur through the transcriptional 
induction of c-myc, a bona fide STAT3 transcriptional target whose levels are increased in the Stat3C/C 
MEFs and that is a well-known inducer of mitochondrial biogenesis [62].  
2.4. STAT3C Triggers Tumorigenic Transformation in Immortalized MEFs 
Similar to primary cells, spontaneously immortalized Stat3C/C MEFs proliferated much faster than their 
wild type counterparts, and displayed loss of inhibition contact with a tendency to grow in multi-layers [24], 
a feature typical of transformed cells, leading us to assess other transformation phenotypes such as focus 
forming ability and anchorage-independent growth. In contrast to their wild type controls, immortalized 
Stat3C/C MEFs were able to give rise to foci on plastic and to colonies in soft agar. HIF activity was 
only partially responsible for these features, which could not be completely reverted by Hif-1α 
silencing (Figure 5A and [24]). Finally, immortal Stat3C/C MEFs were able to give rise to tumors in 
nude mice, confirming full malignant transformation. In vivo growth was totally STAT3-dependent 
and only in part mediated by HIF-1α, as shown by silencing experiments (Figure 5B and [24]). 
Figure 5. Immortalized Stat3C/C MEFs were silenced (white bars) or not (black bars) for 
Hif-1α and their ability to form foci and colonies in soft agar was measured (A). 
Immortalized MEFs of the indicated genotypes and treatments were tested for their ability 
to grow in vivo in nude mice (B). Bars represent mean values ± SEM of three independent 
experiments. Modified from reference [24], according to the journal’s license terms. 
 
In contrast to primary MEFs, which require two oncogenic hits to become transformed, MEFs 
spontaneously immortalized via the 3T3 protocol [63] are known to become competent for 
transformation elicited by a single oncogene [64], suggesting that they have already undergone one 
oncogenic hit. Our results show that low levels of constitutively active STAT3 are sufficient to transform 
primary cells to full malignancy upon immortalization via a 3T3 protocol, suggesting therefore that 
chronic STAT3 activity can act as a first hit in multistep carcinogenesis. This observation might 
explain the key role of STAT3 in the causative link between chronic inflammation and cancer, since 
IL-6-driven STAT3 constitutive activity is a hallmark of chronic inflammation [65]. According to our 
data, cells exposed to chronic IL-6 signalling and displaying continuous STAT3 activation behave like 
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cells that have undergone a first oncogenic mutation, and will therefore be exquisitely sensitive to 
mutagenic events occurring in the inflammatory microenvironment, rich in cytokines, growth factors 
and reactive oxygen species. 
Thus, there are many mechanism(s) through which constitutively active STAT3 sensitizes cells to 
tumorigenic transformation, belonging to classical well described functions as well as to the novel 
metabolic role that we have recently described. A prominent feature is no doubt played by the resistance to 
programmed cell death in response to many different apoptotic stimuli. This is a well-known function of 
STAT3, triggered also in our system by the transcriptional induction of anti-apoptotic genes as well as by 
the reduced mitochondrial Ca2+ uptake [22,24]. The delayed senescence correlating with decreased 
ROS production [22] and the increased proliferation here described likely correlate with the metabolic 
switch towards aerobic glycolysis. Aerobic glycolysis is known to allow rapidly proliferating cells to 
accumulate NADPH and carbon skeletons needed for anabolic reactions as a side-product of glucose 
consumption and ATP production [15]. Additionally, decreased mitochondrial activity will help 
switching the energy balance towards glycolysis allowing at the same time to reduce ROS production, 
which will in turn help cell survival. Another important player in oncogenesis is c-myc, which 
contributes to both increased proliferation and aerobic glycolysis and is a well known STAT3 target. 
Indeed the levels of c-myc are elevated in the Stat3C/C MEFs [66]. Finally, Hif-1α induction may 
initiate the already mentioned feed forward loop involving PKM2 and STAT3 that would contribute 
maintaining high HIF-1α activity, high PKM2:PKM1 ratios and constitutive STAT3 Y-P [26]. 
3. Conclusions 
STAT3 constitutive activation is featured by many types of tumors, and mainly occurs downstream 
of the activation of several different oncogenic pathways [11,67]. Accordingly, STAT3 is required for 
malignant transformation by many different oncogenes that trigger STAT3 Y-P, the prototype being 
vSrc, in part by acting on glucose metabolism as described here. On the other hand, also oncogenes of 
the RAS family have been shown to require STAT3 to transform cells, and this occurs via 
phosphorylation on serine rather than on tyrosine [17,68]. Also S-P STAT3 mediates important 
metabolic functions when localized to the mitochondrion, including preservation of mitochondrial 
activity, induction of aerobic glycolysis and inhibition of the opening of the mitochondrial permeability 
transition pore. Thus, STAT3 appears to be able to promote aerobic glycolysis both from within the 
nucleus and the mitochondrion, while it plays opposite roles on mitochondrial activity, depending on 
the oncogenic signal and the mode of activation (i.e., Y- versus S-P). To further complicate the picture, 
also cytoplasmic, non-phosphorylated STAT3 is implicated in regulating cell survival and energy 
metabolism through autophagy inhibition and, finally, STAT3 acetylation/deacetylation status, regulated 
by oncogenes, transcriptional co-activators and different classes of HDAC enzymes, can affect the 
activities of both Y-P and S-P STAT3. These observations contribute to explain the multiform and 
sometimes contrasting activities described for STAT3, since its functions will vary according to cell 
type-specific target genes, mode of activation and sub-cellular localization. In turn, any condition 
altering the cellular concentration of one specific form of STAT3 is bound to affect the functions of all 
other forms by directly or indirectly altering their abundance, as depicted in Figure 6. This consideration 
needs to be kept in account when designing STAT3-inhibiting drugs. 
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Figure 6. STAT3 can be localized in the mitochondrial matrix, in the nucleus and in the 
cytoplasm, according to specific post-transcriptional modifications triggered by different 
upstream stimuli. Many oncogenic and inflammatory signals mainly induce Y-P STAT3 
nuclear functions that, in addition to known canonical functions, mediate the induction of 
Hif-1α and lead to increased glycolysis and to the initiation of a positive feedback between 
HIF-1α, PKM2 and STAT3. This contributes to supporting cell proliferation and protection 
from apoptosis and senescence. On the other hand, nuclear Y-P STAT3 reduces mitochondrial 
activity by down-regulating, directly or indirectly, many ETC complexes mRNAs, leading 
to reduced mitochondrial respiration, ROS production and apoptosis. In contrast, RAS 
oncogenic signals and MAP kinases trigger S-P and mitochondrial STAT3 functions, 
improving cell survival by enhancing both oxidative phosphorylation and aerobic glycolysis, 
and protecting cells from apoptosis by inhibiting the opening of the mitochondrial 
permeability transition pore (MPTP). Finally, cytoplasmic STAT3 can inhibit autophagy 
by interacting with the cytoplasmic Protein Kinase R (PKR) via its SH2 domain. The 
relative abundance of each form of STAT3 is the result of a balance with the other forms, 
in turn determined by the interplay of different activating and inactivating signals. Black 
arrows: induction; green arrows: interplay; red lines: inhibition. 
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A deeper understanding of the interplay between the differentially phosphorylated forms of STAT3 
and their relative sub-cellular distribution under specific pathological conditions and in different tumor 
types may help designing function-specific inhibitors that may be tested as targeted therapeutic approaches. 
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